Apr 25, 2025
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering
Mar 13, 2025
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
Jan 10, 2025
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
Nov 13, 2024
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 08, 2024
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
Oct 31, 2024
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
Sep 04, 2024
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
May 15, 2024
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
May 15, 2024
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
May 09, 2024
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Apr 02, 2024
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
Mar 14, 2024
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
Jan 03, 2024
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
Apr 15, 2020
Portage provides update on portfolio company, Intensity Therapeutics, Inc.